Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 8
2004 7
2005 9
2006 10
2007 11
2008 7
2009 5
2010 1
2011 1
2012 3
2013 3
2014 5
2015 3
2016 4
2017 1
2018 3
2019 7
2020 17
2021 17
2022 15
2023 12
2024 7

Text availability

Article attribute

Article type

Publication date

Search Results

133 results

Results by year

Filters applied: . Clear all
Page 1
Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma.
Méjean A, Ravaud A, Thezenas S, Colas S, Beauval JB, Bensalah K, Geoffrois L, Thiery-Vuillemin A, Cormier L, Lang H, Guy L, Gravis G, Rolland F, Linassier C, Lechevallier E, Beisland C, Aitchison M, Oudard S, Patard JJ, Theodore C, Chevreau C, Laguerre B, Hubert J, Gross-Goupil M, Bernhard JC, Albiges L, Timsit MO, Lebret T, Escudier B. Méjean A, et al. Among authors: lechevallier e. N Engl J Med. 2018 Aug 2;379(5):417-427. doi: 10.1056/NEJMoa1803675. Epub 2018 Jun 3. N Engl J Med. 2018. PMID: 29860937 Free article. Clinical Trial.
Antitumor immunity induced by antibody-based natural killer cell engager therapeutics armed with not-alpha IL-2 variant.
Demaria O, Gauthier L, Vetizou M, Blanchard Alvarez A, Vagne C, Habif G, Batista L, Baron W, Belaïd N, Girard-Madoux M, Cesari C, Caratini M, Bosco F, Benac O, Lopez J, Fenis A, Galluso J, Trichard S, Carrette B, Carrette F, Maguer A, Jaubert S, Sansaloni A, Letay-Drouet R, Kosthowa C, Lovera N, Dujardin A, Chanuc F, Le Van M, Bokobza S, Jarmuzynski N, Fos C, Gourdin N, Remark R, Lechevallier E, Fakhry N, Salas S, Deville JL, Le Grand R, Bonnafous C, Vollmy L, Represa A, Carpentier S, Rossi B, Morel A, Cornen S, Perrot I, Morel Y, Vivier E. Demaria O, et al. Among authors: lechevallier e. Cell Rep Med. 2022 Oct 18;3(10):100783. doi: 10.1016/j.xcrm.2022.100783. Cell Rep Med. 2022. PMID: 36260981 Free PMC article.
Climate-smart Actions in the Operating Theatre for Improving Sustainability Practices: A Systematic Review.
Pradere B, Mallet R, de La Taille A, Bladou F, Prunet D, Beurrier S, Bardet F, Game X, Fournier G, Lechevallier E, Meria P, Matillon X, Polguer T, Abid N, De Graeve B, Kassab D, Mejean A, Misrai V, Pinar U; Sustainability Task Force of the French Association of Urology. Pradere B, et al. Among authors: lechevallier e. Eur Urol. 2023 Apr;83(4):331-342. doi: 10.1016/j.eururo.2022.01.027. Epub 2022 Feb 10. Eur Urol. 2023. PMID: 35151515 Free article. Review.
Author Reply to Letter to the Editor.
Boissier R, Deledalle FX, Baboudjian M, Lechevallier E. Boissier R, et al. Among authors: lechevallier e. Urology. 2022 Jan;159:257-258. doi: 10.1016/j.urology.2021.10.014. Epub 2021 Oct 30. Urology. 2022. PMID: 34728333 No abstract available.
Reuse and Reprocessing of Endoscopic Instruments: Con.
Baboudjian M, Pradere B, Uleri A, Lechevallier E. Baboudjian M, et al. Among authors: lechevallier e. Eur Urol Focus. 2023 Nov;9(6):859-860. doi: 10.1016/j.euf.2023.09.010. Epub 2023 Sep 23. Eur Urol Focus. 2023. PMID: 37748949
Benefit and Harm of Active Surveillance for Biopsy-proven Renal Oncocytoma: A Systematic Review and Pooled Analysis.
Baboudjian M, Moser D, Yanagisawa T, Gondran-Tellier B, Compérat EM, Ambrosetti D, Daniel L, Bastide C, Shariat SF, Lechevallier E, Diana P, Breda A, Pradere B, Boissier R. Baboudjian M, et al. Among authors: lechevallier e. Eur Urol Open Sci. 2022 May 19;41:8-15. doi: 10.1016/j.euros.2022.04.009. eCollection 2022 Jul. Eur Urol Open Sci. 2022. PMID: 35633831 Free PMC article. Review.
Prostatic artery embolisation versus medical treatment in patients with benign prostatic hyperplasia (PARTEM): a randomised, multicentre, open-label, phase 3, superiority trial.
Sapoval M, Thiounn N, Descazeaud A, Déan C, Ruffion A, Pagnoux G, Duarte RC, Robert G, Petitpierre F, Karsenty G, Vidal V, Murez T, Vernhet-Kovacsik H, de la Taille A, Kobeiter H, Mathieu R, Heautot JF, Droupy S, Frandon J, Barry Delongchamps N, Korb-Savoldelli V, Durand-Zaleski I, Pereira H, Chatellier G; PARTEM study group. Sapoval M, et al. Lancet Reg Health Eur. 2023 Jun 26;31:100672. doi: 10.1016/j.lanepe.2023.100672. eCollection 2023 Aug. Lancet Reg Health Eur. 2023. PMID: 37415648 Free PMC article.
133 results